LifeStance Health Group (NASDAQ:LFST) Given New $17.00 Price Target at KeyCorp

Key Points

• KeyCorp raised its price target on LifeStance Health Group from $15 to $17 and maintained an Overweight rating, implying 25.6% upside from the share price cited in the report.
• LifeStance beat quarterly estimates, reporting adjusted EPS of $0.06 versus $0.04 expected and revenue of $455.9 million versus $431.6 million; revenue grew 25.3% year over year, and the company raised its full-year outlook.
• Insiders sold about 13.8 million shares worth roughly $146.4 million over the past 90 days. Separately, analysts’ consensus rating was Moderate Buy, with an average price target of $13.62.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) had its price objective increased by equities researchers at KeyCorp from $15.00 to $17.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. KeyCorp's price target points to a potential upside of 25.57% from the stock's current price.

A number of other analysts have also recently weighed in on the company. Zacks Research cut LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. Canaccord Genuity Group boosted their target price on LifeStance Health Group from $13.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, September 9th. Weiss Ratings upgraded LifeStance Health Group from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 11th. Barclays increased their price target on LifeStance Health Group from $13.00 to $15.00 and gave the stock an "overweight" rating in a report on Thursday, September 10th. Finally, BTIG Research increased their price target on LifeStance Health Group from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $13.62.

LifeStance Health Group Trading Up 0.8%

NASDAQ LFST opened at $13.54 on Friday. The firm's fifty day moving average is $12.59 and its two-hundred day moving average is $9.46. LifeStance Health Group has a one year low of $5.87 and a one year high of $15.66. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The firm has a market cap of $5.17 billion, a PE ratio of 105.15 and a beta of 1.35.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business had revenue of $455.86 million during the quarter, compared to the consensus estimate of $431.59 million. The company's revenue for the quarter was up 25.3% compared to the same quarter last year. Analysts expect that LifeStance Health Group will post 0.16 earnings per share for the current year.

Insider Buying and Selling

In other LifeStance Health Group news, CTO Vukasin Paunovich sold 44,394 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $481,674.90. Following the transaction, the chief technology officer owned 247,446 shares in the company, valued at approximately $2,684,789.10. The trade was a 15.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.62, for a total value of $144,890,858.34. Following the transaction, the insider directly owned 98,101,407 shares of the company's stock, valued at approximately $1,041,836,942.34. This trade represents a 12.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 13,777,580 shares of company stock valued at $146,433,781 over the last ninety days. Corporate insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Profund Advisors LLC grew its holdings in LifeStance Health Group by 7.1% in the third quarter. Profund Advisors LLC now owns 11,944 shares of the company's stock valued at $144,000 after purchasing an additional 788 shares during the last quarter. Assetmark Inc. increased its position in shares of LifeStance Health Group by 17.0% in the first quarter. Assetmark Inc. now owns 9,419 shares of the company's stock valued at $60,000 after buying an additional 1,367 shares in the last quarter. Signaturefd LLC raised its stake in shares of LifeStance Health Group by 35.6% during the 3rd quarter. Signaturefd LLC now owns 5,357 shares of the company's stock worth $64,000 after buying an additional 1,405 shares during the last quarter. Everhart Financial Group Inc. raised its stake in shares of LifeStance Health Group by 1.3% during the 3rd quarter. Everhart Financial Group Inc. now owns 112,844 shares of the company's stock worth $1,358,000 after buying an additional 1,435 shares during the last quarter. Finally, Allworth Financial LP raised its stake in shares of LifeStance Health Group by 7.7% during the 2nd quarter. Allworth Financial LP now owns 26,532 shares of the company's stock worth $284,000 after buying an additional 1,889 shares during the last quarter. Hedge funds and other institutional investors own 85.50% of the company's stock.

Key Headlines Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: BTIG Research raised its price target to $20 from $18 and maintained a Buy rating. The new target implies 48.7% upside from the cited $13.45 share price. Article: LifeStance Health Group Stock Price Target Raised at BTIG Research
• Positive Sentiment: LifeStance reported third-quarter adjusted earnings of $0.06 per share, beating estimates of $0.04, and revenue of $455.9 million, above the $431.6 million consensus. Revenue increased 25.3% year over year, and the company raised its full-year outlook—supporting investor optimism about growth and profitability. Article: LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance's services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.